Incyte Corporation $INCY Shares Newly Acquired by Sigma Planning Corp

Key Points

• Sigma Planning Corp acquired 10,108 Incyte shares worth approximately $1.23 million during the third quarter, while other institutional investors also increased or initiated positions. Institutions collectively own 96.97% of Incyte.
• Incyte’s third-quarter revenue rose 14% year over year to $1.56 billion, beating estimates, and the company raised its 2026 sales guidance to $5.21 billion-$5.30 billion, supported by strong Opzelura and oncology-product growth.
• Despite improved operating performance and pipeline momentum, Incyte posted a roughly $785 million GAAP net loss due largely to a $1.23 billion Vega Therapeutics acquisition charge. Analysts remain mixed, with a consensus “Hold” rating and an average price target of $131.43.

Sigma Planning Corp bought a new stake in Incyte Corporation (NASDAQ:INCY - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 10,108 shares of the biopharmaceutical company's stock, valued at approximately $1,227,000.

Several other large investors have also made changes to their positions in INCY. Signaturefd LLC increased its holdings in Incyte by 14.6% in the 3rd quarter. Signaturefd LLC now owns 4,786 shares of the biopharmaceutical company's stock worth $581,000 after purchasing an additional 608 shares in the last quarter. Citizens Financial Group Inc. RI lifted its holdings in shares of Incyte by 56.6% during the third quarter. Citizens Financial Group Inc. RI now owns 5,815 shares of the biopharmaceutical company's stock worth $706,000 after purchasing an additional 2,102 shares during the period. Sowell Financial Services LLC acquired a new position in shares of Incyte during the third quarter worth $202,000. Kendall Capital Management increased its holdings in Incyte by 7.2% in the third quarter. Kendall Capital Management now owns 13,700 shares of the biopharmaceutical company's stock valued at $1,662,000 after purchasing an additional 920 shares during the period. Finally, Capital Investment Advisors LLC bought a new position in Incyte during the 3rd quarter worth $216,000. Institutional investors and hedge funds own 96.97% of the company's stock.

Insider Buying and Selling at Incyte

In related news, insider Pablo Cagnoni sold 10,801 shares of the company's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the sale, the insider owned 183,200 shares in the company, valued at approximately $23,002,592. This represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is owned by corporate insiders.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $1.56 billion, exceeding the roughly $1.46 billion analyst estimate. The adjusted loss of $3.60 per share was also narrower than expected, reflecting solid underlying business performance. Incyte Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: Incyte raised its 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance increased to $1.10 billion-$1.12 billion, supported by strong demand. Incyte Raises 2026 Sales Outlook
• Positive Sentiment: Key products performed well: Opzelura sales increased 36% to $255 million, Hematology and Oncology portfolio sales rose 38% to $235 million, and Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Third-Quarter Revenue and Guidance Update
• Positive Sentiment: Pipeline sentiment also improved after early data characterized Incyte’s G12D program as competitive in pancreatic cancer, while a partner began a Phase 1 study combining INCA33890 with another therapy in colorectal cancer. Incyte G12D Pipeline Update
• Neutral Sentiment: Management’s earnings call highlighted $3.9 billion in cash, cash equivalents and marketable securities at quarter-end, providing financial flexibility for development and acquisitions. Incyte Q3 Earnings Call Transcript
• Negative Sentiment: Incyte reported a GAAP net loss of approximately $785 million, or $3.86 per share, versus a profit in the prior-year quarter. The result was primarily driven by a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. Incyte Q3 Loss and Vega Acquisition Charge
• Negative Sentiment: Although guidance was raised, some investors viewed the new full-year sales range as below the level implied by consensus expectations, limiting the positive reaction to the earnings beat.

Wall Street Analyst Weigh In

INCY has been the subject of several recent research reports. Citigroup reissued a "buy" rating on shares of Incyte in a research note on Monday, August 3rd. HC Wainwright restated a "buy" rating on shares of Incyte in a research report on Tuesday. Truist Financial upped their price objective on shares of Incyte from $105.00 to $115.00 and gave the company a "hold" rating in a research note on Wednesday, October 14th. Mizuho upped their price target on shares of Incyte from $121.00 to $137.00 and gave the company an "outperform" rating in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group began coverage on Incyte in a research report on Thursday, August 20th. They issued a "buy" rating and a $152.00 price objective for the company. Twelve investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Incyte has a consensus rating of "Hold" and an average target price of $131.43.

Incyte Stock Performance

Shares of NASDAQ:INCY opened at $116.80 on Friday. Incyte Corporation has a 52-week low of $89.25 and a 52-week high of $132.60. The business's 50 day simple moving average is $120.62 and its two-hundred day simple moving average is $108.07. The firm has a market cap of $23.68 billion, a P/E ratio of 14.88, a PEG ratio of 4.83 and a beta of 0.74.

Incyte (NASDAQ:INCY - Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping analysts' consensus estimates of ($3.93) by $0.33. The company had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. Incyte had a return on equity of 29.93% and a net margin of 27.71%. Incyte's revenue for the quarter was up 14.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.26 earnings per share. On average, equities analysts forecast that Incyte Corporation will post 1.97 earnings per share for the current fiscal year.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.